Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance

Journal of Clinical Psychopharmacology

Volumn 20, Issue 3, 2000, Pages 328-337

  Troy, Steven M ^a   Lucki, Irwin ^b   Unruh, Mary A ^c   Cevallos, William H ^a   Leister, Cathie A ^a   Martin, Patrick T ^a   Furlan, Patricia M B ^b   Mangano, Richard ^a  

^a WYETH AYERST RESEARCH   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WYETH AYERST RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TRIAZOLAM; ZALEPLON; ZOLPIDEM;

ADULT; ARTICLE; COGNITIVE DEFECT; DRUG ACTIVITY; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; INSOMNIA; LEARNING; MALE; MEMORY; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOMOTOR PERFORMANCE; SCORING SYSTEM;

ACETAMIDES; ADOLESCENT; ADULT; AFFECT; ASSOCIATION LEARNING; ATTENTION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; LEARNING; MALE; MEMORY; MENTAL RECALL; MIDDLE AGED; PSYCHOMOTOR PERFORMANCE; PYRIDINES; PYRIMIDINES; QUESTIONNAIRES; SEX CHARACTERISTICS; TRIAZOLAM;

EID: 0034117467     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200006000-00007     Document Type: Article

References (26)

1. Maczaj M. Pharmacologic treatment of insomnia. Drugs 1993;45: 45-55.
2. Bixler EO, Kales A, Soldatos CR, Kales JD, Healy S. Prevalence of sleep disorders in the Los Angeles metropolitan area. Am J Psychiatry 1979;136:1257-62.
3. Lugaresi E, Zucconi M, Bixler EO. Epidemiology of sleep disorders. Psychiatry Ann 1987;17:446-53.
4. Consensus Development Conference. Drugs and insomnia: the use of medication to promote sleep. JAMA 1984;251:2410-4.
5. Johnson LC, Chernik DA. Sedative-hypnotics and human performance. Psychopharmacology (Berl) 1982;76:101-13.
6. Wesensten NJ, Balkin TJ, Belenk GL. Effects of daytime administration of zolpidem versus triazolam on memory. Eur J Clin Pharmacol 1995;48:115-22.
7. Dietrich B, Farr I. Zaleplon: dose-response evaluation in primary insomnia [Abstract 24]. In: Chase MH, Roth T, O'Connor C, eds. Sleep research. Los Angeles: Brain Information Services/Brain Research Institute, 1995:116.
8. Beer B, Ieni J, Wu WH, Clody D, Amorusi P, Rose J, Mant T, Gaudreault J, Cato A, Stern W. A placebo-controlled evaluation of single, escalating doses of CL 284,846, a nonbenzodiazepine hypnotic. J Clin Pharmacol 1994;34:335-44.
9. Greenblatt DJ, Harmatz JS, von Voltke LL, Ehrenberg BL, Harrel L, Corbett K, Counihan M, Graf JA, Darwish M, Mertzanis P, Martin PT, Cevallos WH, Shader RI. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther 1998;64:553-61.
10. Salva P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem: therapeutic implications. Clin Pharmacokinet 1995;29:142-53.
11. Kroboth PD, Smith RB, Silver MR, Rault R, Sorkin MI, Puschett JB, Juhl RP. Effects of end stage renal disease and aluminum hydroxide on triazolam pharmacokinetics. Br J Clin Pharmacol 1985;19:839-42.
12. Robin DW, Lee MH, Hasan SS, Wood AJJ. Triazolam in cirrhosis: pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1993;54:630-7.
13. Allen D, Curran HV, Lader M. The effects of single doses of CL 284, 846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers. Eur J Clin Pharmacol 1993;45:313-20.
14. Vermeeren A, Danjou PE, O'Hanlon JF. Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance. Hum Psychopharmacol 1998;13:S98-S107.
15. th European College of Neuropsychopharmacology (ECNP). Paris, France, 31 Oct to 4 Nov. 1998. Eur Neuropsychopharmacol 1998;8[Suppl 2]:S297.
16. Berlin I, Warot D, Hergueta T, Molinier P, Bagot C, Puech A. Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J Clin Psychopharmacol 1993;13:100-6.
17. Rush CR, Griffiths RR. Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers. J Clin Psychopharmacol 1996;16:146-57.
18. Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmacol 1980;10:189-209.
19. Markowitz JS, Brewerton TD. Zolpidem-induced psychosis. Ann Clin Psychiatry 1996;8:89-91.
20. Ansseau M, Pitchot W, Hanseene M, Moreno AG. Psychotic reactions to zolpidem [letter]. Lancet 1992;339:809.
21. Pies RW. Dose-related sensory distortions with zolpidem. J Clin Psychiatry 1995;56:35-6.
22. Gengo FM, Gabos C. Antihistamines, drowsiness, and psychomotor impairment: central nervous system effect of cetirizine. Ann Allergy 1987;59:53-7.
23. Roehrs T, Merlotti L, Zorick F, Roth T. Sedative, memory, and performance effects of hypnotics. Psychopharmacology (Berl) 1994; 116:130-4.
24. Evan SM, Funderburk FR, Griffiths RR. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther 1990;255:1246-55.
25. Lister RG. The amnesic action of benzodiazepines in man. Neurosci Biobehav Rev 1985;9:87-94.
26. Ballon TJ, O'Donnell VM, Wesentensen N, McCann U, Belenky G. Comparison of the daytime sleep performance effects of zolpidem versus triazolam. Psychopharmacology (Berl) 1992;107:83-8.